Picture of Novozymes A/S logo

NSIS B Novozymes A/S News Story

0.000.00%
dk flag iconLast trade - 00:00
Basic MaterialsBalancedLarge CapNeutral

Bernstein sees normalising consumer chemicals growth in 2024

** Bernstein says end of destocking suggests more normalised
2024 growth for consumer chemical makers that supply the home
and personal care (HPC) and food and beverages (F&B) sectors
    ** After destocking weighed on organic sales growth in 2023,
the brokerage expects volumes to recover this and next year,
with only low single-digit percent price increases
    ** It expects higher volumes from Q4 2023 to continue in
2024 with a rapid recovery of +3.5% in Q1, which should grow
gradually up to 4.7% in Q4 2024
    ** The broker sees some price declines in Q1, which will
turn positive in Q2 and remain positive until the end of 2024
    ** Bernstein expects +4.5% organic sales growth in 2024
supported by growth in both HPC and F&B end-markets
    ** The broker keeps "outperform" on International Flavors &
Fragrances  IFF.N , DSM-Firmenich  DSFIR.AS , Evonik  EVKn.DE ,
and Novozymes  NSISb.CO 
    ** It maintains "market perform" on Croda  CRDA.L , Givaudan
 GIVN.S  and Symrise  SY1G.DE , and "underperform" on BASF
 BASFn.DE 

 (Reporting by Marta Frąckowiak)
 ((marta.frackowiak@thomsonreuters.com))

Recent news on Novozymes A/S

See all news